

Advancing quality use of medicines in NSW

Fortnightly TAG Mail – resources list

25th April 2024

NSW TAG ACTIVITIES

Open email discussions

- **1. Hospital-funded Shingrix**: Are DTCs are receiving requests to approve use and funding of Shingrix in their immunocompromised patient populations that are outside the NIP criteria and what is your approach to these potentially very expensive requests? **Closes 1**st **May 2024**
- 2. Hospital/district approaches to supplying and stocking COVID-19 antiviral medicines: Hospitals are requested to outline any strategies they are considering/implementing concerning supply of COVID-19 antivirals to ED patients and stocking of COVID-19 antivirals for inpatient use. Closes 1st May 2024

Recently completed email discussions

- Handling of medicines by perfusionists
- DTC assessment process for non-GMO phage therapy applications
- DTC pharmacists in NSW
- Patient prioritisation for discharge medication list provision
- Missing medications from wards
- Medication reviews for inpatients in remote Multi-Purpose Services.

Upcoming TAG meetings

NSW TAG Finance Committee Meeting: Friday 3 May 2024 9.00-9.45am NSW TAG Management Committee Meeting: Friday 3 May 2024 9.45-11.00am

Updated TAG publications

Updated SGLT2 inhibitor medicines for diabetes-Consumer Information Leaflet - link Contact Sasha Bennett at <u>sasha.bennett@svha.org.au</u> for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

ISMP: Updates List of Error-Prone Abbreviations, Symbols, and Dose Designations - <u>link</u>
SPS NHS UK: Preparation risk assessments for Advanced Therapy Medicinal Products and in-vivo Gene Therapies - <u>link</u>

AP: - Partnered pharmacist medication charting and prescribing in Australian hospitals - link

AP: Cardiovascular disease risk: a practical summary of the 2023 guideline - link

BJCP: Thirst and drugs: A study in the WHO's pharmacovigilance database - link

BJCP: The emergence of psychedelics in the management of pain and opioid use disorder - link

BMJ: Impact of large scale, multicomponent intervention to reduce PPI overuse - link

BMJQS: Paediatric medication incident reporting: a multicentre comparison study of medication errors identified at audit, detected by staff and reported to an incident system - <u>link</u>

Drug Safety: Drug–Drug Interactions and Actual Harm to Hospitalized Patients: A Multicentre Study Examining the Prevalence Pre- and Post-Electronic Medication System Implementation - link

EHJ: Ten years of direct oral anticoagulants: lessons learned and challenges ahead - link

EJHP: Policy recommendations for medication safety improvement for ICUs - link

HospPediatrics: Decreasing Prescribing Errors in Antimicrobial Stewardship Program - link

IJCP: Delabeling of allergy to beta-lactam antibiotics a prospective study evaluating cost savings - <u>link</u> JPS: An Analysis of Incident Reports Related to EMM: How They Change Over Time - link

JPPR: - Standard of practice in palliative care for pharmacy services - link

Lancet GH: - Mechanisms and management of loss of response to anti-TNF therapy in Crohn's disease - link

Lancet PH:_Beyond misinformation: developing a public health prevention framework for managing information ecosystems - link

MDPI: Redesigning Medication Management in the Emergency Department: The Impact of Partnered Pharmacist Medication Charting - <u>link</u>

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Join the first psychotropic medicines standard launch link
- Have your say on the Aged Care Infection Prevention and Control Guide link

NSW Health

- Public health warning: severe opioid overdoses in Penrith area link
- Could it be sepsis? link
- HIV treatment for people in NSW who are not eligible for Medicare (GL2024 003)
- Prenatal Screening and Diagnostic Testing for Fetal Chromosomal Abnormality (PD2024 013)

TGA

- Nitrosamine impurities acceptable intakes update link
- All medicinal cannabis products supplied to Australian patients must meet quality standards link

REPORTS AND PUBLICATIONS - AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found here

Australian Government Department of Health

- Japanese encephalitis (JEV) resources - link

Australian Institute for Health and Welfare (AIHW)

- Alcohol and other drug treatment services in Australia: early insights link
- Health of children: Australia's health topic summary update link
- Trends in cannabis availability, use, and treatment in Australia, 2013-14 to 2021-22 link
- People with disability in Australia link
- Alcohol, tobacco and other drugs in Australia link
- Dementia Awareness Survey link

TGA

- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPAR: Beyfortus

REPORTS AND PUBLICATIONS - INTERNATIONAL

Agency for Healthcare Research and Quality (AHRQ) USA

- Rapid Evidence Product: Patient Safety Practices Focused on Sepsis Prediction and Recognition - link

British Menopause Society

- Management of unscheduled bleeding on hormone replacement therapy (HRT) - link

Canadian Agency for Drugs and Technologies in Health

- Buprenorphine-Based Formulations for Opioid Use Disorder in Correctional Settings - link

electronic Medicines Compendium (eMC) (UK)

- New products
- -- Mepsevii (vestronidase alfa) recombinant form of human beta-glucuronidase (GUS) for non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome), a lyosomal storage disorder characterised by the deficiency of GUS
- -- Erleada (apalutamide) 240 mg new strength reduces tablet load for patients on 240mg daily dose
- -- Oxylan (oxycodone hydrochloride) now available in 15mg, 30mg and 60mg strengths (in addition to 5mg, 10mg, 20mg, 40mg and 80mg) for severe pain given at 12-hourly intervals
- -- Pylera (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) for use in combination with omeprazole for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

- Talzenna (talazoparib tosylate) - monotherapy in patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced/metastatic breast cancer, and in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated

electronic Medicines Compendium (eMC) (UK)

- New or extended indications
- -- Mavenclad (cladribine) broadening of the therapeutic indication to include treatment of relapsing forms of multiple sclerosis (previously only for highly active multiple sclerosis)
- -- Olumiant (baricitinib) new indications of paediatric atopic dermatitis (in those aged ≥2 years who are candidates for systemic therapy) and juvenile idiopathic arthritis (in those aged ≥2 years who have had an inadequate response or intolerance to DMARDs)
- -- Takhzyro (lanadelumab) indication of routine prevention of recurrent attacks of hereditary angioedema extended to cover use in younger age group from age 2 years, and 150 mg in 1 ml prefilled syringe added as a new strength for paediatric use
- -- Xromi (hydroxycarbamide) for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age (previously from 2 years). Clinical efficacy and safety data from the BABY HUG trial were added to support this license extension

European Medicines Agency (EMA)

- New recommendations to strengthen supply chains of critical medicines - link

Food and Drug Administration (FDA) USA

- New Drug approvals
- -- Pivya (pivmecillinam), for uncomplicated urinary tract Infections
- -- tovorafenib (Ojemda) for patients with relapsed/refractory BRAF-altered pediatric low-grade glioma
- -- lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS
- -- <u>nogapendekin alfa inbakicept-pmln</u> (Anktiva) for BCG-unresponsive non-muscle invasive bladder cancer
- -- alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
- -- <u>Lumisight</u> pegulicianine to use as an optical imaging agent for the detection of cancerous tissue
- -- Zevtera (<u>ceftobiprole</u> medocaril sodium) to treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
- -- ciltacabtagene autoleucel (Carvykti) for multiple myeloma after 1 or more lines of therapy

MIMS UK

- New tool to help clinicians consider the environmental impact of prescribing - link

Medicines and Healthcare products Regulatory Agency (MHRA)

- Fosdenopterin licensed for the treatment of molybdenum cofactor deficiency - link

NHS England

- Psychological therapies for severe mental health problems – implementation guidance 2024 - link

National Institute for Health and Care Excellence (NICE) UK

- Endometriosis: diagnosis and management, updated (NG73)

National Institute for Health and Care Research (NIHR) Commentaries

- Pelvic organ prolapse: self-management of pessaries can be a good option - link

Royal Pharmaceutical Society

- ... updates patient safety professional standards - link

The King's Fund (UK)

- The role of integrated care systems in improving dementia diagnosis - link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- Revised SPCs
- -- Ameluz (5-aminolevulinic acid hydrochloride) artificial daylight added as alternative light source for photodynamic therapy with Ameluz for the treatment of Actinic keratosis on the face and scalp. In section 4.4, new warning added advising intensive lesion preparation might lead to increased pain
- -- Bondronat (ibandronic acid) information updated on atypical fractures of other long bones, such as the ulna and tibia, which have also been reported in patients receiving long-term treatment. As with atypical femoral fractures, these occur after minimal, or no trauma
- -- Cidomycin (gentamicin sulfate) consider alternative treatment options or genetic testing in patients with mitochondrial DNA mutations (particularly nucleotide 1555 A to G substitution in the 12S rRNA gene) or maternal history of these, including when gentamicin serum levels are in range
- -- Cotellic (cobimetinib hemifumarate) stomatitis included as ADR (frequency 'very common')
- -- Denzapine (clozapine) shelf-life for the unopened product has changed from 6 months to 2 years. Patients are advised to take a dose as soon as it is drawn into oral dispenser and not store doses for later use. SPC now advises that the product must be stored below 25°C and shaken prior to each use
- -- Fabrazyme (agalsidase beta) excreted in human milk and a decision must be made whether to discontinue breastfeeding or to discontinue/abstain from therapy. Section 6.6 now recommends prompt dilution after reconstitution, to minimise protein particle formation over time
- -- Inderal (propranolol hydrochloride) depression included as an ADR with unknown frequency
- -- Pradaxa (dabigatran) for VTE treatment and prevention of recurrent VTE in paediatric patients updated to include use from the time the child is able to swallow soft food [previously from birth] to less than 18 years of age
- -- Rifadin (rifampicin) and Rifinah (isoniazid, rifampicin) contraindicated for use with lurasidone as it markedly decreases the exposure of lurasidone. Additionally, cerebellar syndrome is added as an ADR of unknown frequency, with a warning that this has been reported mainly in patients with chronic kidney disease
- -- Sarclisa (isatuximab) interference with indirect Coombs test may persist for ≥6 months after last infusion. Advice that no dose adjustment recommended in patients with mild-severe renal impairment expanded to cover those with end-stage renal disease based on pharmacokinetic analysis
- -- Semaglutide containing products intestinal obstruction included as an ADR (frequency 'not known'). Section discussing lack of interaction with warfarin updated to include interaction between acenocoumarol and semaglutide-containing products
- -- Tysabri (natalizumab) injections administered by a HP outside a clinical setting (e.g. at home) may be considered for patients who have previously tolerated at least 6 doses of natalizumab well, i.e. who have not experienced hypersensitivity reactions
- -- Vokanamet (metformin hydrochloride, canagliflozin hemihydrate) data describing outcomes following in utero exposure to metformin added. These do not indicate an increased risk of congenital malformations. Manufacturer advises Vokanamet should not be used in pregnancy due to lack of data for use of canagliflozin or Vokanamet in pregnant women
- -- Wegovy (semaglutide) intestinal obstruction added as an ADR (frequency not known). Information in section 4.5 on interaction with warfarin updated to discuss other coumarin derivatives and advise frequent INR monitoring if semaglutide is started in those on such treatment
- Risk minimisation materials
- -- etrasimod (<u>Velsipity</u>) prescriber checklist highlights important potential risks & recommended tests before & during treatment, a patient card raises awareness about embryofoetal toxicity in pregnant females exposed to etrasimod, and a patient/caregiver guide provides important safety information

EMA

- New safety information for healthcare professionals: advice to CHMP on new Rybelsus tablets (oral semaglutide) link
- PRAC concludes available evidence does not support causal links between GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide) and suicidal and self-injurious thoughts and actions link
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) <u>8-11 April 2024</u>

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

Food and Drug Administration (FDA) USA

- FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies - link

Institute for Safe Medication Practices (ISMP) USA

- ISMP Updates List of Error-Prone Abbreviations, Symbols, and Dose Designations link
- Medication Safety Alert! April 18, 2024
- -- Patient Death After Inadvertent Infusion of PRN Medication Hanging on Bedside IV Pole link

Specialist Pharmacy Services NHS UK

- How to perform preparation risk assessments for Advanced Therapy Medicinal Products (ATMPs) and in-vivo Gene Therapies (ATMPs) link
- Medication Safety Update March 2024
- Using folic acid with phenytoin link
- Switching between mesalazine oral tablet preparations link

TGA

- Update: Extension to the shortage of Zactin Tabs (fluoxetine 20mg dispersible tablets) link
- Extension to the shortage of Vyvanse 60mg (lisdexamfetamine dimesilate) capsules link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)

- Approaches to medication history taking in different hospital settings: A scoping review link
- The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparininduced thrombocytopenia: A systematic review - link

Annals of Internal Medicine

- Update Alert: Nonpharmacologic and Pharmacologic Treatments of Adult Patients with Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians link
- Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians $\underline{\text{link}}$
- Excessive Alcohol Use and Alcohol Use Disorders: A Policy Brief of the American College of Physicians $\underline{\text{link}}$
- Assessing clinician utilization of next-generation antibiotics against resistant gram-negative infections in U.S. hospitals: A retrospective cohort study <u>link</u>

Australian Prescriber

- Biologic therapies for severe asthma with persistent type 2 inflammation link
- Partnered pharmacist medication charting and prescribing in Australian hospitals link
- Diagnosis and management of obstructive sleep apnoea in adults link
- Assessing, communicating and managing cardiovascular disease risk: a practical summary of the 2023 guideline link
- Letter: Evidence-based management of menopause link
- Letter: Digital health: dashboards, dashboards everywhere link
- New drugs
- -- Andusomeran & raxtozinameran for prevention of COVID-19 disease
- -- Faricimab for neovascular age-related macular degeneration and diabetic macular oedema
- -- Relugolix+estradiol+norethisterone for symptomatic uterine fibroids
- TGA Medicines Safety Update summary: Updated warnings of faricimab (Vabysmo) retinal vasculitis risk link

British Journal of Clinical Pharmacology

- Thirst and drugs: A study in the World Health Organization's pharmacovigilance database - link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

- From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder link
- A randomized, double-blind study to compare the efficacy and safety of nalbuphine nasal spray and injectable solution in patients after orthopaedic interventions and traumatological procedures link
- Letter: Bleeding in patients on concurrent treatment with serotonin reuptake inhibitor (SRI) and acetylsalicylic acid (ASA) compared with ASA alone: a pharmacovigilance study link
- Administration mode matters for 5-fluorouracil therapy: Physiologically based pharmacokinetic evidence for avoidance of myelotoxicity by continuous infusion but not intravenous bolus <u>link</u>

British Journal of General Practice

- Weight Management with Orlistat in Type 2 Diabetes – An Electronic Healthcare Records Study - link

British Medical Journal (BMJ)

- Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial link
- Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study link – SPS commentary
- Advances in management of heart failure link
- Impact of large scale, multicomponent intervention to reduce proton pump inhibitor overuse in integrated healthcare system: difference-in-difference study <u>link</u> <u>SPS commentary</u>
- Refocusing the World Health Organization's model list of essential medicines on the needs of low and middle income countries link
- Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study <u>link</u>
- How to communicate about climate change with patients link
- Oxycodone initiation in Australia (2014–2018): Sociodemographic factors and preceding health service use link

BMJ Open

- Colchicine for the treatment of patients with COVID-19: an updated systematic review and metaanalysis of randomised controlled trials - link

BMJ Quality and Safety

- Paediatric medication incident reporting: a multicentre comparison study of medication errors identified at audit, detected by staff and reported to an incident system - link

Circulation

- Patient-Centered Adult Cardiovascular Care: A Scientific Statement From the American Heart Association link
- Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era link
- Environmental Exposures and Pediatric Cardiology: A Scientific Statement From the American Heart Association <u>link</u>
- Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association <a href="https://link.org/

Diabetes, Obesity and Metabolism

- Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis - link

Drug Safety

- Drug–Drug Interactions and Actual Harm to Hospitalized Patients: A Multicentre Study Examining the Prevalence Pre- and Post-Electronic Medication System Implementation - <u>link</u>

European Heart Journal

- Ten years of direct oral anticoagulants: lessons learned and challenges ahead - link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au An initiative of NSW clinical pharmacologists & pharmacists

European Journal of Allergy and Clinical Immunology

- A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination - <u>link</u>

European Journal of Hospital Pharmacy

- Development and prioritisation of policy recommendations for medication safety improvement for intensive care units: a European Association of Hospital Pharmacists Special Interest Group Delphi Study link
- Letter: Home antibiotic therapy in elastomeric infusion pumps past, present and future link
- Adverse drug effect in the context of drug shortage: the CIRUPT prospective study from the French pharmacovigilance network link

Heart

- Preconception counselling in women of reproductive age attending cardiology clinics in Scotland link
- Outcomes in patients treated with loop diuretics without a diagnosis of heart failure: a retrospective cohort study <u>link</u>

Hospital Pediatrics

- Decreasing Prescribing Errors in Antimicrobial Stewardship Program-Restricted Medications - link

International Journal of Clinical Pharmacy

- Delabeling of allergy to beta-lactam antibiotics in hospitalized patients: a prospective study evaluating cost savings link
- Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer link
- Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study \underline{link}
- Clinical impact of an individualised clinical pharmacy programme into the memory care pathway of older people: an observational study link
- Exploring the impact of anticholinergic burden on urinary independence: insights from a post-stroke cohort of older adults link

International Journal for Quality in Health Care

- Process management program to prevent falls in hospitalized patients with neuropsychiatric disorders: a quality improvement program - link

JAMA

- Using Effect Scores to Characterize Heterogeneity of Treatment Effects link
- Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments link
- Uterine Fibroids link
- Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus link
- Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban link
- Patient page: What Is Hepatitis D Infection? link
- Stewardship Prompts to Improve Antibiotic Selection for Pneumonia: The INSPIRE Randomized Clinical Trial $\underline{\text{link}}$
- Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract Infection: The INSPIRE Randomized Clinical Trial link
- Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications link
- Interstitial Lung Disease: A Review link
- Letter: Industry Payments to US Physicians by Specialty and Product Type- link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

JAMA Cardiology

- Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial - link

JAMA Internal Medicine

- Acute Cardiac Events in Hospitalized Older Adults with Respiratory Syncytial Virus Infection link
- Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin <u>link</u>
- Antihypertensive Medication and Fracture Risk in Older Veterans Health Administration Nursing Home Residents <u>link</u>
- Inappropriate Diagnosis of Pneumonia Among Hospitalized Adults link

JAMA Network Open

- Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis $\underline{\text{link}} \underline{\text{SPS commentary}}$
- SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure: A Systematic Review and Meta-Analysis <u>link</u>

Journal of the American Geriatrics Society

- Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta-analysis - link

Journal of Clinical Oncology

- Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study link
- Use of Sodium Thiosulfate as an Otoprotectant in Patients with Cancer Treated with Platinum Compounds: A Review of the Literature link

Journal of Patient Safety

- An Analysis of Incident Reports Related to Electronic Medication Management: How They Change Over Time - link

Journal of Pharmaceutical Analysis

- Advancing drug safety and mitigating health concerns: High-resolution mass spectrometry in the levothyroxine case study - link

Journal of Pharmacy Practice and Research (JPPR)

- Standard of practice in palliative care for pharmacy services link
- Antibiotics administered as continuous intravenous infusion over 24 hours by elastomeric devices to patients treated at home: a study of infusion efficiency link

Journal of Thrombosis and Haemastasis

- Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients - <u>link</u>

Lancet

- B-cell non-Hodgkin lymphomas link
- Systemic lupus erythematosus link

Lancet Gastroenterology and Hepatology

- Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study <u>link</u>
- Pathophysiology and therapeutic options for cirrhotic portal hypertension link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

Lancet HIV

- Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens - link

Lancet Neurology

- Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment - \underline{link}

Lancet Oncology

- Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study - <u>link</u>

Lancet Psychiatry

- Prevalence of multimorbidity in people with and without severe mental illness: a systematic review and meta-analysis - link

Lancet Public Health

- Beyond misinformation: developing a public health prevention framework for managing information ecosystems - <u>link</u>

Molecular Diversity Preservation International (MDPI) - Pharmacy Journal

- Predictive Modeling of Factors Influencing Adherence to SGLT-2 Inhibitors in Ambulatory Care: Insights from Prescription Claims Data Analysis <u>link</u>
- Redesigning Medication Management in the Emergency Department: The Impact of Partnered Pharmacist Medication Charting on the Time to Administer Pre-Admission Time-Critical Medicines, Medication Order Completeness, and Venous Thromboembolism Risk Assessment <a href="https://link.google.com/link.goo

Medical Journal of Australia

- Perspective: Towards national paediatric health clinical practice guidelines - link

New England Journal of Medicine

- Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer link SPS commentary
- Guidance on Energy and Macronutrients across the Life Span link
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma link
- Retinoblastoma Origins and Destinations link

Pediatrics (American Academy of Pediatrics)

- Antibiotics for Acute Sinusitis in Children: A Meta-Analysis - link - commentary

Pharmacotherapy

- Antiviral influenza treatments and hemorrhage-related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database <u>link</u>
- Warfarin dosage in a postpartum woman while breastfeeding: A case report link

Stroke

- Intravenous Alteplase Versus Best Medical Therapy for Patients with Minor Stroke: A Systematic Review and Meta-Analysis - link

CONSULTATIONS (new additions in bold)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Consultation on the Aged Care Infection Prevention and Control Guide, closing 15 May 2024 - link

TGA

- Consultation: clarification of how Clinical Decision Support System (CDSS) software is regulated, closes on 6 May 2024 - link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- Episode 161 - Managing hypercholesterolaemia - link

FDA Division of Drug Information is presenting a series of CE webinars

- Fraudulent Drugs: You're Using What? - May 21, 2024 - register

MJA Podcasts

- <u>Episode 13</u>: Advice for clinicians on salt and nutrients found in Australian yeast extracts and tomato sauces
- Episode 12: developments in treating kidney disease

Purple Pen Podcast

- PPP 160 - Social and Cultural Considerations in Antimicrobial Use - 14 April 2024

NEW EVENTS

See cumulative TAGMail listing for previously highlighted events

AHHA

- Post-Budget Health Leaders Roundtable, Canberra, 17 May 2024 10:00-16:00 - register

SHPA

- MM2024, 14-16 November 2024, Adelaide BioMed City - call for abstracts

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists